VJOncology is committed to improving our service to you

ELCC 2018 | Clinical trial data for TKIs in ALK-rearranged NSCLC

VJOncology is committed to improving our service to you

Silvia Novello

Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the efficacy of different tyrosine kinase inhibitors (TKIs) on ALK-rearranged non-small cell lung cancer (NSCLC) at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter